5-(氨基甲基)-2-噻吩甲腈 | 227279-10-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 5-(氨基甲基)-2-噻吩甲腈
• 英文名称: 2-cyano-5-(aminomethyl)thiophene
• 英文别名: 5-(aminomethyl)thiophene-2-carbonitrile；5-cyano-2-(aminomethyl)thiophene；5-Aminomethyl-2-cyanothiophene
• CAS: 227279-10-9
• 化学式: C₆H₆N₂S
• 分子量: 138.193
• InChiKey: FHYNZXSHHPBOBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  78
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5-(氨基甲基)-2-噻吩甲腈 在 N-甲基吗啉 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 D-diphenylalanyl-L-prolyl-[(5-cyano-2-thienyl)methyl]amide
  参考文献：
  名称：

  Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1

  摘要：

  A series of noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at PI was investigated. While the amidrazone and the amine series displayed limited oral absorption, the amidine series demonstrated generally good oral absorption and strong antithrombotic activity; the single-digit picomolar K-i achieved from this series is among the best yet reported. The present work highlights the benzamidine compound 11f (LB30812) that exhibits excellent overall profiles of potency, oral absorption and antithrombotic efficacy. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00093-8
• 作为产物：
  描述：

  5-(N,N-Boc2-aminomethyl)thiophene-2-carbonitrile 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 5-(氨基甲基)-2-噻吩甲腈
  参考文献：
  名称：

  Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1

  摘要：

  A series of noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at PI was investigated. While the amidrazone and the amine series displayed limited oral absorption, the amidine series demonstrated generally good oral absorption and strong antithrombotic activity; the single-digit picomolar K-i achieved from this series is among the best yet reported. The present work highlights the benzamidine compound 11f (LB30812) that exhibits excellent overall profiles of potency, oral absorption and antithrombotic efficacy. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00093-8

文献信息

• [EN] NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS 2-PIPERIDIN-1-YL-ACETAMIDE UTILISABLES EN TANT QU'INHIBITEURS DE TANKYRASE
  申请人：NOVARTIS AG

  公开号：WO2013012723A1

  公开（公告）日：2013-01-24

  The present invention provides for compounds of formula (I), wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.

  本发明提供了式(I)的化合物，其中R1-R5和L在此处定义。本发明还提供了包含式(I)化合物的药物组合物和组合物，以及将这些化合物用作坦基酶抑制剂以及用于治疗Wnt信号和坦基酶1和2信号相关疾病的用途，包括但不限于癌症。
• MASP-2 INHIBITORS AND METHODS OF USE
  申请人：Omeros Corporation

  公开号：US20210171512A1

  公开（公告）日：2021-06-10

  The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

  本公开提供了具有MASP-2抑制活性的化合物，这些化合物的组合物，以及制造和使用这些化合物的方法。
• COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS
  申请人：Tully David C.

  公开号：US20080176901A1

  公开（公告）日：2008-07-24

  The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.

  该发明提供了化合物及其药物组合物，用于调节通道激活蛋白酶，并使用这些化合物治疗、改善或预防与通道激活蛋白酶相关的疾病的方法，包括但不限于前列腺素酶、PRSS22、TMPRSS11（例如TMPRSS11B、TMPRSS11E）、TMPRSS2、TMPRSS3、TMPRSS4（MTSP-2）、酶蛋白酶（MTSP-1）、CAP2、CAP3、胰蛋白酶、卡特普西蛋白A或中性粒细胞弹性蛋白酶。
• Efficacious and Orally Bioavailable Thrombin Inhibitors Based on a 2,5-Thienylamidine at the P1 Position:  Discovery of <i>N</i>-Carboxymethyl-<scp>d</scp>-diphenylalanyl-<scp>l</scp>-prolyl[(5-amidino-2-thienyl)methyl]amide
  作者：Koo Lee、Cheol Won Park、Won-Hyuk Jung、Hee Dong Park、Sun Hwa Lee、Kyung Ha Chung、Su Kyung Park、O Hwan Kwon、Myunggyun Kang、Doo-Hee Park、Sang Koo Lee、Eunice E. Kim、Suk Kyoon Yoon、Aeri Kim

  DOI：10.1021/jm030025j

  日期：2003.8.1

  enzyme in the blood coagulation, has been a target for antithrombotic therapy. Orally active thrombin inhibitors would provide effective and safe prophylaxis for venous and arterial thrombosis. We conducted optimization of a highly efficacious benzamidine-based thrombin inhibitor LB30812 (3, K(i) = 3 pM) to improve oral bioavailability. Of a variety of arylamidines investigated at the P1 position,

  凝血酶是凝血中的关键酶，一直是抗血栓治疗的目标。口服活性凝血酶抑制剂可为静脉和动脉血栓形成提供有效和安全的预防。我们对高效的基于苯甲am的凝血酶抑制剂LB30812（3，K（i）= 3 pM）进行了优化，以提高口服生物利用度。在P1位置研究的各种芳基idine胺中，2,5-噻吩基idine胺有效替代了苯amam，而不会损害凝血酶的抑制作用和口服吸收。通常，在N末端位置进行磺酰胺和磺酰胺衍生化可提供高效的凝血酶抑制剂，但具有适度的口服吸收，而可吸收性强的N-氨基甲酸酯衍生物在S9馏分中的代谢稳定性有限。目前的工作最终是发现含有N-羧甲基和2,5-噻吩啶的化合物22，该化合物表现出最有利的抗凝血和抗血栓形成活性以及口服生物活性（K（i）= 15 pM; F =在大鼠，狗和猴子中分别为43％，42％和15％）。在大鼠和兔子的静脉血栓形成模型中，以重量计，该化合物显示出比低分子量肝素依诺肝素更有效
• Non-covalent inhibitors of urokinase and blood vessel formation
  申请人：Corvas International, Inc.

  公开号：US20020037857A1

  公开（公告）日：2002-03-28

  Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have Pi a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.

  提供了一种具有作为尿激酶非共价抑制剂活性并在减少或抑制血管形成方面具有活性的新化合物。这些化合物具有Pi基团，其中含有一个酰胺基团或鸟胺基团或其衍生物。这些化合物在体外用于监测纤溶酶原激活剂水平，在体内用于治疗通过抑制尿激酶或降低其活性而得到改善的病症，以及用于治疗血管形成与病理病变相关的病理状况。